178 related articles for article (PubMed ID: 37146405)
1. Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease.
Lien HE; Berg HF; Halle MK; Trovik J; Haldorsen IS; Akslen LA; Krakstad C
EBioMedicine; 2023 Jun; 92():104595. PubMed ID: 37146405
[TBL] [Abstract][Full Text] [Related]
2. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Mauland KK; Wik E; Hoivik EA; Kusonmano K; Halle MK; Berg A; Haugland HK; Øyan AM; Kalland KH; Stefansson IM; Akslen LA; Krakstad C; Trovik J; Werner HM; Salvesen HB
Oncotarget; 2017 Feb; 8(6):9696-9707. PubMed ID: 28039471
[TBL] [Abstract][Full Text] [Related]
3. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
[TBL] [Abstract][Full Text] [Related]
5. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
Singh M; Spoelstra NS; Jean A; Howe E; Torkko KC; Clark HR; Darling DS; Shroyer KR; Horwitz KB; Broaddus RR; Richer JK
Mod Pathol; 2008 Jul; 21(7):912-23. PubMed ID: 18487993
[TBL] [Abstract][Full Text] [Related]
6. Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma.
Zhang X; Cao G; Diao X; Bai W; Zhang Y; Wang S
Dis Markers; 2022; 2022():5240046. PubMed ID: 35320951
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
[TBL] [Abstract][Full Text] [Related]
8. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.
Westin SN; Broaddus RR; Deng L; McCampbell A; Lu KH; Lacour RA; Milam MR; Urbauer DL; Mueller P; Pickar JH; Loose DS
Cancer Biol Ther; 2009 Nov; 8(22):2126-35. PubMed ID: 19755863
[TBL] [Abstract][Full Text] [Related]
9. WNT5A gene and protein expression in endometrial cancer.
Wasniewski T; Kiezun J; Krazinski BE; Kowalczyk AE; Szostak B; Wierzbicki PM; Kiewisz J
Folia Histochem Cytobiol; 2019; 57(2):84-93. PubMed ID: 31198984
[TBL] [Abstract][Full Text] [Related]
10. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
13. N-cadherin identifies human endometrial epithelial progenitor cells by in vitro stem cell assays.
Nguyen HPT; Xiao L; Deane JA; Tan KS; Cousins FL; Masuda H; Sprung CN; Rosamilia A; Gargett CE
Hum Reprod; 2017 Nov; 32(11):2254-2268. PubMed ID: 29040564
[TBL] [Abstract][Full Text] [Related]
14. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel subgroup of endometrial cancer patients with loss of thyroid hormone receptor beta expression and improved survival.
Piqué DG; Greally JM; Mar JC
BMC Cancer; 2020 Sep; 20(1):857. PubMed ID: 32894083
[TBL] [Abstract][Full Text] [Related]
17. Markers of the epithelial-mesenchymal transition in cells of endometrial carcinoma.
Nesina IP; Iurchenko NP; Buchynska LG
Exp Oncol; 2018 Oct; 40(3):218-222. PubMed ID: 30284998
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia.
Wu S; Du Y; Beckford J; Alachkar H
J Transl Med; 2018 Jun; 16(1):170. PubMed ID: 29925392
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
20. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
